News

Cimzia is a PEGylated anti-TNF (Tumor Necrosis Factor), which has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha. Cimzia showed rapid and sustained

The PILLAR study [Protease Inhibitor TMC435 trial assessing the optimaL dose and duration as once daiLy Anti-viral Regimen] was a five-arm, global phase 2b randomized, double-blind, placebo controlled

Vismodegib is an investigational, oral, targeted medicine which selectively inhibits signaling in the Hedgehog pathway and treats adults with advanced basal cell carcinoma (BCC). The vismodegib application includes

Access said it will provide CobOral and CobaCyte siRNA formulations for evaluation of gene knockdown following oral and intravenous administration. RNAi is initiated by introducing small fragments of

A multi-center clinical study, whic involved 442 patients and used European Union (EU) approved cetuximab, led to the approval. In the trial, 222 patients received cetuximab plus cisplatin

The company which works for The National Institutes of Health (NIH), has been awarded funding from Capital Management for the NIH Integrated Research Facility (IRF) commissioning support project,

The contract is valued at up to $24m for the upcoming two years. The company expects to facilitate the development of Rx100, a radiomitigant countermeasure drug used against

The program intends to develop an advanced system for early cancer detection by employing acoustic liquid handling for arraying and MALDI mass spectrometry preparation. Stanford University Canary Center

As per the agreement, ORCA will receive €1,058,000 to carry out the first phase of the project, with an expected additional funding of about €5m on achieving specific